U.S. Interactive Media and Services Stock News

Fiserv (FISV) is back in focus after recent trading left the stock down about 17% over the past month and about 16% over the past 3 months, which has sharpened attention on its current valuation. See our latest analysis for Fiserv. Stepping back, Fiserv’s recent slide fits into a longer weak patch, with the share price down 27.9% year to date and the 1 year total shareholder return declining 72.6%. This points to fading momentum and a more cautious market view on its risk and growth...

uniQure (NasdaqGS:QURE) reported positive initial data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. Several patients in the initial low dose cohort experienced meaningful seizure reduction, with an encouraging safety profile. This is the first clinical efficacy and safety readout for AMT-260, expanding uniQure's pipeline beyond Huntington's disease. uniQure, trading at $49.04, is drawing fresh attention as AMT-260 moves from concept to early clinical...

Vicor stock performance puts spotlight on recent returns Vicor (VICR) has drawn fresh attention after a sharp move in the share price, with the stock up about 25% over the past month and about 81% over the past 3 months. That short term performance sits alongside a year to date total return of about 188% and an approximate 641% total return over the past year. This is prompting investors to reassess how current fundamentals align with the new share price. See our latest analysis for Vicor. At...

Leidos Holdings (LDOS) has attracted fresh attention after securing new roles in the ExCURSion energy program with DARPA and landing four awards under the U.S. Department of State’s Evolve IT modernization contract. See our latest analysis for Leidos Holdings. Despite the new DARPA and Evolve contract roles, Leidos Holdings’ share price has come under pressure, with the 30 day share price return down 15.79% and the year to date share price return down 42.16%. Over the same period, the 3 year...

Enterprise Products Partners (EPD) is drawing fresh attention after recent analyst estimate revisions highlighted rising confidence ahead of its upcoming earnings report, where year-over-year growth in both earnings and revenue is currently expected. See our latest analysis for Enterprise Products Partners. At a share price of US$37.13, Enterprise Products Partners has seen a 1-day share price return of 1.95% and a 7-day share price return of 1.87%, while the 30-day share price return is down...

Recent Share Performance Context Kosmos Energy (KOS) has drawn attention after its stock fell 24% over the past month and 14% over the past 3 months, while its year-to-date return remains positive. See our latest analysis for Kosmos Energy. The recent slide in Kosmos Energy’s share price, including a 6.5% decline on the day and a 7.6% fall over the past week, comes after a very strong year to date share price return of 157.6%. The 1 year total shareholder return of 18.6% sits against weaker 3...

AT&T Fiber was named the top home internet provider in a recent Opensignal report. The service outperformed peers on speed, reliability, and video quality metrics. The recognition highlights outcomes from AT&T’s multi year investment in fiber infrastructure. For investors tracking NYSE:T, this third party endorsement focuses attention on AT&T’s consumer internet offering rather than its traditional telecom operations. The stock last closed at $22.81, with the share price down 9.7% over the...

Talphera, Inc. ( NASDAQ:TLPH ) insiders who bought shares over the past year were rewarded handsomely last week. The...

Insiders who acquired US$611.2k worth of Sintx Technologies, Inc.'s ( NASDAQ:SINT ) stock at an average price of...

Last week, DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) insiders, who had purchased shares in the previous 12 months...

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Boston Scientific’s Watchman heart device is increasingly being implanted during combined cardiac procedures instead of as a standalone treatment. This shift in medical practice has reduced standalone Watchman procedure volumes and is expected to keep revenue for the product line roughly flat through Q3 2026. The change reflects how doctors are rethinking procedure planning, with implications for Boston Scientific’s growth mix and product planning. For investors watching Boston Scientific...

Earlier this week, SoFi Technologies launched Composer by SoFi, an AI-powered investing platform that lets retail investors create, test, and automate sophisticated strategies in plain language and deploy community-built portfolios. The move deepens SoFi’s push to make “Wall Street-grade” systematic investing tools and AI financial coaching available inside a single, consumer-focused money app. Next, we’ll explore how giving retail investors AI-driven, rules-based investing tools could...

Comcast has launched accelerated same-day delivery of Xfinity WiFi equipment in major markets. The rollout is tied to a nationwide Minions & Monsters retail and digital experience with Universal. Xfinity customers can access exclusive perks and augmented reality features connected to the film promotion. Comcast, traded as NasdaqGS:CMCSA, is rolling out this service while its stock trades around $22.8. Shares are down 3.6% over the past week and 9.5% over the past month, with longer term...

Index inclusion puts TowneBank in focus TowneBank (TOWN) has been added to the S&P Banks Select Industry Index, an event that can shift how institutional investors view and access the stock. This index inclusion may influence trading activity, liquidity, and how TowneBank fits into diversified banking portfolios. See our latest analysis for TowneBank. TowneBank’s recent index inclusion comes on the back of steady share price momentum, with a 90 day share price return of 6.76% and a 1 year...

Why Synchrony Financial’s Pet Resort Partnership Matters for Investors Synchrony Financial (SYF) recently announced a partnership with Pet Resort Hospitality Group that makes CareCredit the preferred financing solution across 40 pet resort locations in 12 states, covering services from daycare to training. See our latest analysis for Synchrony Financial. For investors watching Synchrony Financial, the recent Pet Resort Hospitality Group deal arrives as the stock trades at US$75.04, with a 30...

If you are wondering whether Target stock still offers value after its recent run, this article walks through what the current price might be implying about the company. At a last close of US$134.11, Target has posted returns of 0.5% over the past week, 6.8% over the past month, 33.4% year to date and 43.5% over the past year, which naturally raises questions about how much upside or downside may be left. Recent commentary around Target has focused on how the stock reflects changing...

Atlassian (TEAM) stock is back in focus after the company reported 32% year-over-year revenue growth in Q3 FY2026, driven by its expanding cloud business and a Service Collection now above US$1b in annual recurring revenue. See our latest analysis for Atlassian. Despite Atlassian’s strong Q3 FY2026 revenue update, the stock is trading at US$81.35, with the share price down year to date but a 90 day share price return of 22.4% hinting at stabilising momentum after a much weaker 1 year total...

If you are wondering whether Space Exploration Technologies at around US$156 still offers reasonable value, the next sections walk through what the current price might be implying about the stock. Over the past week, the share price has fallen 22.6% to a last close of US$156.11, and is now down 3.0% year to date, which may have changed how some investors view its potential and risk. Recent coverage around Space Exploration Technologies has focused on its position within the telecom sector...

Recent coverage of 1st Source Corporation highlighted its strong historical financial performance, with consistent net interest margin expansion and earnings per share increasing annually by 12.7% over the past five years. Investors are also focusing on the bank’s forward price-to-book ratio of 1.4x, which underscores market interest in how its valuation stacks up against its underlying performance. With this backdrop of growing earnings and margin strength, we’ll examine how the news could...

Intuit (INTU) is in focus after recent share price pressure, with the stock down around 19% over the past month and about 40% over the past 3 months from its recent levels. See our latest analysis for Intuit. That recent share price slide comes after a much weaker run overall, with Intuit’s 30 day share price return down 19.3% and its 1 year total shareholder return down 65.7%. This points to fading momentum and a sharply reassessed risk and reward profile. If sharp moves in Intuit have you...

At the recently held 23rd annual dbAccess Global Consumer Conference, Kimberly-Clark outlined progress on its Powering Care plan, citing nine consecutive quarters of volume and share growth and advancing a US$3.00 billion productivity program, alongside the launch of Pull-Ups Learning Layer technology in Canada. This combination of operational execution and targeted product innovation in core categories such as diapers and training pants may influence how investors assess Kimberly-Clark’s...

If you are wondering whether Bank of America stock still offers value at current levels, this article walks through what the market price may be implying about the company. The stock last closed at US$57.91, with returns of 1.9% over the past 7 days, 11.8% over the past 30 days, 3.5% year to date, 26.8% over the past year, 121.1% over 3 years and 60.1% over 5 years. These figures give useful context before looking at valuation. Recent headlines around Bank of America have focused on its...

In recent days, GENESIS Pharma announced it has expanded its commercial partnership with Alnylam Pharmaceuticals to include Sweden, Finland, Denmark, and Norway, while Alnylam also entered an AI-driven RNAi drug discovery collaboration with Inceptive Nucleics valued at up to US$2.00 billion. Together, these moves both broaden access to Alnylam’s existing RNAi therapies in new European markets and aim to make its discovery engine faster and more efficient through AI-enhanced oligonucleotide...